© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
Among the TRML insiders holding of N/A of the stake in company, MCDADE MARK, director, holds the largest shares of 448.43K. KULKARNI SANDEEP CHIDAMBAR, CEO, is the second largest TRML insider with ownership of 7K shares. , , stands third with possession of - shares of that stake.
A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own TRML shares is N/A, representing N/A of the company's common stock.
N/A, in the last quarter, reduced its stake in TRML by N/A restricting it's holding to - shares of worth nearly -. N/A also lessened N/A of the TRML shares from its portfolio, reducing its holding to - shares of worth -. N/A also shunned TRML shares holding by N/A last quarter which brought its holding to - shares worth -.
As per its latest 13F filing, N/A increased its stake in TRML by N/A in the last quarter. The institutional holder raised its holding to - shares having worth more than -. N/A also added N/A more shares of TRML to its portfolio, raising its holding to - shares of worth -. N/A also increased its TRML shares holding by N/A which brought its holding to - shares worth -.
The insider with the most stakes in TRML is MCDADE MARK , director at the company. Additionally, TRML stock is highly held by CEO Kulkarni Sandeep Chidambar and N/A N/A among others.
Company executives, directors, and other insiders own N/A percent of Tourmaline Bio, Inc.'s stock. Within the last six months, there have been 0 transaction(s) in which TRML insiders have sold stock, totaling 0 shares. Insiders that have sold shares include .
There have been 2 transaction(s) during the past 6-months in which Tourmaline Bio, Inc. insiders have bought stock, totalling 7000 shares
Around 12.22K Tourmaline Bio, Inc. shares are held by insiders, which represents about N/A of TRML stock.
TRML director, MCDADE MARK holds the largest portfolio of the company's shares. TRML shares owned by MCDADE total nearly 448.43 thousand.
N/A is the largest institutional owner in TRML which holds - shares worth - or N/A of the total TRML shares outstanding followed by N/A with ownership of - shares representing N/A of the TRML ownership. N/A is the third largest stakeholder with - shares or N/A of the ownership worth more than -.
Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the TRML is concerned, it is a stock which is optionable.
Number of TRML shares short is 2.08M. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.
As of today, 25.64M shares of TRML are outstanding.
Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, TRML has 12.55M shares in float.
Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for TRML is 11.21.